CRISPR Therapeutics AG (CRSP) Non Operating Income (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Non Operating Income data on file, last reported at $8.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 39.75% year-over-year to $8.2 million; the trailing twelve-month figure through Mar 2026 stood at $81.2 million (down 12.39% YoY), and the FY2025 full-year result was $86.6 million, down 16.65% from the prior year.
• Non Operating Income slipped to $8.2 million in Q1 2026, from $24.8 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $28.0 million in Q4 2024 to a low of $363000.0 in Q1 2022.
• A 5-year average of $17.2 million and a median of $20.0 million in 2023 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income tumbled 81.43% in 2022 and soared 3410.19% in 2023, its largest moves.
• Tracing CRSP's Non Operating Income over 5 years: stood at $11.5 million in 2022, then surged by 74.04% to $20.0 million in 2023, then soared by 39.91% to $28.0 million in 2024, then fell by 11.48% to $24.8 million in 2025, then sank by 67.07% to $8.2 million in 2026.
• Business Quant data shows CRSP's Non Operating Income at $8.2 million in Q1 2026, $24.8 million in Q4 2025, and $26.2 million in Q3 2025.